Bio-Bridge Science, Inc. Receives Approval for Acquisition of Xinheng Baide Biotechnology Co. Ltd.

OAK BROOK, Ill.--(BUSINESS WIRE)--Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human infectious diseases announced today that it had received a certificate of approval from the Department of Commerce of Inner Mongolia Autonomous Region of the PRC for approving the acquisition of Xinheng Baide Biotechnology Co. Ltd. BGES has one month to close the transaction, and obtain the new business license. The transaction is expected to close before the end of July.

MORE ON THIS TOPIC